Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ADC Therapeutics SA (ADCT : NYSE)

• Company Description    ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland. Number of Employees: 193

• Price / Volume Information    Yesterday's Closing Price: $3.39 Daily Weekly Monthly 20 Day Moving Average: 1,201,546 shares Shares Outstanding: 127.19 (millions) Market Capitalization: $431.18 (millions) Beta: 1.83 52 Week High: $4.98 52 Week Low: $2.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.39% -18.58% 12 Week -17.92% -24.12% Year To Date -3.97% -11.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BIOPOLE ROUTE DE LA CORNICHE 3B - EPALINGES,V8 1066 CHE ph: 41-21-653-0200 fax: - nicole.riley@adctherapeutics.com http://www.adctherapeutics.com

• General Corporate Information    Officers Ameet Mallik - Chief Executive Officer and Director Ron Squarer - Chairman of the Board of Directors Jose Carmona - Chief Financial Officer Robert Azelby - Director Peter Hug - Director Peer Information ADC Therapeutics SA (CORR.) ADC Therapeutics SA (RSPI) ADC Therapeutics SA (CGXP) ADC Therapeutics SA (BGEN) ADC Therapeutics SA (GTBP) ADC Therapeutics SA (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H0036K147 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 127.19 Most Recent Split Date: (:1) Beta: 1.83 Market Capitalization: $431.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 5.45 EPS Growth vs. Year Ago Period: 41.67% vs. Previous Quarter: -425.00% Sales Growth vs. Year Ago Period: -9.47% vs. Previous Quarter: -9.57% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -44.70 12/31/25 - -47.26 09/30/25 - -55.38 Current Ratio 03/31/26 - 4.09 12/31/25 - 4.37 09/30/25 - 4.63 Quick Ratio 03/31/26 - 4.02 12/31/25 - 4.31 09/30/25 - 4.34 Operating Margin 03/31/26 - -173.02 12/31/25 - -175.30 09/30/25 - -221.97 Net Margin 03/31/26 - -173.02 12/31/25 - -175.30 09/30/25 - -221.97 Pre-Tax Margin 03/31/26 - -171.95 12/31/25 - -174.06 09/30/25 - -220.51 Book Value 03/31/26 - -1.70 12/31/25 - -1.50 09/30/25 - -2.12 Inventory Turnover 03/31/26 - 0.66 12/31/25 - 0.40 09/30/25 - 0.39 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©